Status: Planned First registered on: 15/04/2019
Last updated on: 23/04/2019
1. Study identification
EU PAS Register NumberEUPAS29401
Official titleAdvancing the Patient Experience in COPD Registry
Study title acronymAPEX COPD
Study typeObservational study
Brief description of the studyThe initiative aims to improve primary care for COPD patients. It will bring together electronic medical records with patient reported information and observations, and present this to clinicians in a structured and clinically relevant format at the point of care. This will be achieved using modern technology, including FHIR, electronic patient surveys, and standardized data collection, and will be guided by a network of COPD physicians in primary and secondary care. Impact will be maximised through Research publications regarding treatment effectiveness and associated risk in mild to moderate COPD, reason for therapy switch/escalation and hidden undiagnosed and untreated COPD patients in primary care. A strong network of COPD primary care physicians in the US is driving the initiative and will ensure impact on clinical practice through academic organisations and research outputs.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameOptimum Patient Care Ltd
Centre location5 Coles Lane, Oakington, CB24 3BA, Cambridge, United Kingdom
Details of (Primary) lead investigator
Title Professor
Last name Price
First name David
Is this study being carried out with the collaboration of a research network?
Yes
DARTNet Institute
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

United States
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed27/12/201827/12/2018
Start date of data collection01/07/2019
Start date of data analysis02/09/2019
Date of interim report, if expected
Date of final study report30/12/2022
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesBoehringer Ingelheim, Inc.40
Charities
Government body
Research councils
EU funding scheme
OtherOptimum Patient Care Ltd.60
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 15 Coles Lane
Address line 2 
Address line 3 
CityCambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom
Phone number (incl. country code)44-1223-967855 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg
Public Enquiries
Title Professor 
Last name Price 
First name David 
Address line 15 Coles Lane 
Address line 2 
Address line 3 
CityCambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom 
Phone number (incl. country code)44-1223-967855 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg 
Top